---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003346"
form_type: "8-K"
ticker: null
cik: "0000793171"
company_name: "Vitro Biopharma, Inc."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:21:16.696312+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vitro Biopharma appoints Thomas Ohrt as CFO; former CFO Nathan Haas to consult

## Summary
- Nathan Haas resigned as CFO effective Jan 18, 2024; entered into Settlement and Consulting Agreements.
- Haas to receive $175k unpaid bonus upon qualified financing or direct listing; 2023 bonus by April 1, 2024.
- Haas will serve as strategy consultant for four months at $15,000/month.
- Thomas Ohrt appointed CFO, salary $250k/year, eligible for $125k target performance bonus.
- Ohrt served as controller since Jan 2021; 35 years of financial leadership experience.

## SEC filing metadata
- accession: 0001493152-24-003346
- form_type: 8-K
- cik: 0000793171
- company_name: Vitro Biopharma, Inc.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/0001493152-24-003346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003346
- JSON: https://secwatch.observer/filing/0001493152-24-003346.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003346.txt

## Key facts
- Executive change
  Nathan Haas resigned as Chief Financial Officer at Vitro Biopharma, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Pursuant to the Settlement Agreement, the parties confirmed Mr. Haas’s resignation as Chief Financial Officer, effective January 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/0001493152-24-003346-index.htm
- Executive change
  Thomas W. Ohrt was appointed as Chief Financial Officer at Vitro Biopharma, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 22, 2024, Thomas W. Ohrt was appointed the Company’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/0001493152-24-003346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.